Non-Invasive, Low-Cost Test Provides Early Detection—and Ongoing Monitoring of Previously Diagnosed Patients—Offering New Hope in the Fight Against Cancer
SAN DIEGO, Sept. 10, 2015 /PRNewswire/ -- Pathway Genomics, a global precision medical diagnostics company, announced the launch of CancerIntercept™, its first liquid biopsy, a non-invasive screening test designed for early cancer detection and monitoring, for as low as $299.
The test detects mutations that are commonly associated with lung, breast, ovarian, colorectal cancers and melanoma, as well as mutations that occur less frequently in other cancer types (such as pancreatic, head and neck, thyroid, gastric and prostate cancers). View an animation of how CancerIntercept works here.
The test is offered for two general populations: CancerIntercept™ Detect is the first liquid biopsy designed to detect tumor DNA in high-risk but otherwise healthy patients; CancerIntercept™ Monitor monitors patients with active or previously diagnosed cancer. Both programs use advanced DNA analysis to identify small DNA fragments that are shed from cancer cells and released into the bloodstream. The tests analyze the presence of 96 frequently occurring DNA mutations in nine cancer genes.
"Early detection is the single most important factor in ensuring successful treatments and improved survival rates," said Jim Plante, CEO and founder of Pathway Genomics. "Cancer patients and those at risk for the disease can take proactive steps to safeguard their health and fight back against some of the most virulent forms of the disease."
In addition, with CancerIntercept Monitor, physicians are able to supplement more invasive tissue biopsies and scans with liquid biopsies to monitor cancer treatment efficacy, disease progression and recurrence. CancerIntercept Monitor can also be ordered with personalized Clinical Trial Matching for later stage cancer patients.
"Rising levels of tumor DNA may indicate progression of the cancer before there is clinical or imaging evidence of tumor growth" said Dr. Glenn Braunstein, MD and Chief Medical Officer of Pathway Genomics. "Our liquid biopsy tests may also detect new mutations that occur over time and signal that the patient is becoming resistant to current therapy."
Testing can be initiated through the patient's treating physician or through Pathway's online physician referral network. For patients and physicians requesting repeat testing on a scheduled basis, a deeply discounted subscription service is available.
CancerIntercept Detect and CancerIntercept Monitor are offered through Pathway's integrated system, which streamlines the entire testing process from initial order to delivery of test reports. Key components of the system include physicians who will review online requisitions and order the tests; mobile phlebotomists to draw blood samples at the patient's home or office; and Pathway's medical oncology support team, who will discuss results with the patient's treating physician upon a positive result. All positive results are released via the patient's treating physician. Results are delivered approximately two to three weeks after testing.
About Pathway Genomics Since its founding in 2008, Pathway Genomics has rapidly become a leader in the commercial healthcare industry. Pathway Genomics' success lies in its commitment to deliver innovative healthcare solutions. The company's program with IBM Watson is the first of its kind. The program is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual's health history.